



Deposited via The University of York.

White Rose Research Online URL for this paper:

<https://eprints.whiterose.ac.uk/id/eprint/228103/>

Version: Published Version

Article:

Bhatty, Asad, Wilkinson, Chris, Batra, Gorav et al. (2024) Standardized and hierarchically classified heart failure and complementary disease monitoring outcome measures: European Unified Registries for Heart Care Evaluation and Randomised Trials (EuroHeart). European Heart Journal — Quality of Care & Clinical Outcomes. qcae086. ISSN: 2058-1742

<https://doi.org/10.1093/ehjqcco/qcae086>

Reuse

This article is distributed under the terms of the Creative Commons Attribution (CC BY) licence. This licence allows you to distribute, remix, tweak, and build upon the work, even commercially, as long as you credit the authors for the original work. More information and the full terms of the licence here:

<https://creativecommons.org/licenses/>

Takedown

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.

Standardized and hierarchically classified heart failure and complementary disease monitoring outcome measures: European Unified Registries for Heart Care Evaluation and Randomised Trials (EuroHeart)

Asad Bhatt^{1,2,3,*}, Chris Wilkinson^{4,5}, Gorav Batra⁶, Suleman Aktaa^{1,3}, Adam B. Smith^{1,2}, Ali Wahab^{1,2,3}, Sam Chappell^{1,2}, Joakim Alfredsson⁷, David Erlinge⁸, Jorge Ferreira⁹, Ingibjörg J. Guðmundsdóttir^{10,11}, Þórdís Jóna Hrafnkelsdóttir^{10,11}, Inga Jóna Ingimarsdóttir^{10,11}, Alar Irs¹², András Jánosi¹³, Zoltán Járjai¹⁴, Manuel Oliveira-Santos¹⁵, Bogdan A. Popescu¹⁶, Peter Vasko⁷, Dragos Vinereanu¹⁶, Jonathan Yap¹⁷, Raffaele Bugiardini¹⁸, Edina Cenko¹⁸, Ramesh Nadarajah^{1,2,3}, Matthew R. Sydes^{19,20,21}, Stefan James⁶, Aldo P. Maggioni¹⁸, Lars Wallentin⁶, Barbara Casadei²², and Chris P. Gale^{1,2,3}

¹Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Leeds, UK; ²Leeds Institute for Data Analytics, University of Leeds, Leeds, UK; ³Department of Cardiology, Leeds Teaching Hospitals NHS Trust, Leeds, UK; ⁴Hull York Medical School, University of York, York, UK; ⁵Academic Cardiovascular Unit, South Tees NHS Foundation Trust, James Cook University Hospital, Middlesbrough, UK; ⁶Department of Medical Sciences, Cardiology and Uppsala Clinical Research Centre, Uppsala University, Uppsala, Sweden; ⁷Linköping University Hospital, Linköping, Sweden; ⁸Lund University, Sweden; ⁹Hospital de Santa Cruz, Centro Hospitalar de Lisboa Ocidental, Portugal; ¹⁰Department of Cardiology, Landspítali University Hospital, Reykjavik, Iceland; ¹¹Department of Health Sciences, Faculty of Medicine, University of Iceland, Reykjavik, Iceland; ¹²Tartu University Hospital, Estonia; ¹³György Gottsegen National Cardiovascular Institute, Hungary; ¹⁴South Buda Center Hospital, Szent Imre Teaching Hospital, Hungary; ¹⁵Cardiology Department, Unidade Local de Saúde de Coimbra, Portugal; ¹⁶University of Medicine and Pharmacy Carol Davila, Emergency Institute for Cardiovascular Diseases, Bucharest, Romania; ¹⁷National Heart Centre Singapore, Singapore; ¹⁸ANMCO Research Centre, Heart Care Foundation, 50121 Florence, Italy; ¹⁹MRC Clinical Trials Unit at UCL, University College London, London, UK; ²⁰BHF Data Science Centre, Health Data Research UK, London, UK; ²¹Data for R&D Programme, NHS England, London, UK; and ²²Division of Cardiovascular Medicine, NIHR Oxford Biomedical Research Centre, University of Oxford, Oxford

Received 23 September 2024; accepted 2 October 2024; online publish-ahead-of-print 9 October 2024

Aims

The lack of standardized definitions for heart failure outcome measures limits the ability to reliably assess the effectiveness of heart failure therapies. The European Unified Registries for Heart Care Evaluation and Randomised Trials (EuroHeart) aimed to produce a catalogue of internationally endorsed data definitions for heart failure outcome measures.

Methods and results

Following the EuroHeart methods for the development of cardiovascular data standards, a working group was formed of representatives from the European Society of Cardiology Heart Failure Association and other leading heart failure experts. A systematic review of observational and randomized clinical trials identified current outcome measures, which was supplemented by clinical practice guidelines and existing registries for contemporary definitions. A modified Delphi process was employed to gain consensus for variable inclusion and whether collection should be mandatory (Level 1) or optional (Level 2) within EuroHeart. In addition, a set of complementary outcome measures were identified by the

* Corresponding author. Email: A.N.Bhatt@leeds.ac.uk


working group as of scientific and clinical importance for longitudinal monitoring for people with heart failure. Five Level 1 and two Level 2 outcome measures were selected and defined, alongside five complementary monitoring outcomes for patients with heart failure.

Conclusion

We present a structured, hierarchical catalogue of internationally endorsed heart failure outcome measures. This will facilitate quality improvement, high quality observational research, registry-based trials, and post-market surveillance of medical devices.

Graphical Abstract

Standardized and hierarchically classified heart failure and complementary disease monitoring outcome measures. HF, heart failure.



Keywords

Outcomes definitions • Heart failure • EuroHeart • Quality of care

Key Learning Points

What is already known

- Heart failure is a common long-term condition that is associated with significant morbidity and mortality.
- Inconsistent cardiovascular outcome measures and definitions hinder interpretation between trials.
- Existing consensus documents have sought to standardize heart failure outcome measures for use in trials. However, they are not specific to heart failure, address acute decompensated heart failure, or lack hierarchical specification.

What this study adds

- A structured and hierarchical catalogue of heart failure outcome measures that are internationally endorsed by ESC affiliations and working groups including the Heart Failure Association.
- These include five Level 1 outcomes (mandatory within EuroHeart), two Level 2 outcomes (optional), and five complementary outcomes (optional).
- Addition of complementary heart failure outcomes that are useful to monitor in patients with heart failure.

Introduction

Heart failure is a common long-term condition associated with substantial morbidity and mortality, reduced quality of life, and high economic burden.^{1–3} Advances in research study design, generalizability of results, and their translation into clinical practice is contingent upon consistent, clear definitions of clinical outcomes that are widely applicable.⁴ Inconsistent outcome measures and definitions in studies of the same intervention hinders interpretation of the effect of the interventions being tested.⁴ Previous work from the Academic Research Consortium (ARC)^{5,6} and the Standardised Data Collection for Cardiovascular Trials Initiative⁷ sought to standardize outcome measures and their definitions for cardiovascular disease. However, these outcome measures are not specific to contemporary heart failure management,⁷ limited to acute decompensated heart failure,⁶ or lack hierarchical grading of the perceived importance of the outcome measure to health care providers, trialists, and regulators.⁵

The European Unified Registries for Heart Care Evaluation and Randomised Trials (EuroHeart) is a European Society of Cardiology (ESC) initiative that aims to improve the quality of care and outcomes for patients with cardiovascular disease. To achieve this, EuroHeart has published a suite of internationally endorsed data standards for cardiovascular diseases using an established methodology.^{8–12} EuroHeart is prospectively and continuously capturing patient data across participating countries from multiple geographies as part of a collaborative international registry of patients with acute coronary syndrome,¹³ and will now expand to other cardiovascular disease areas including heart failure. EuroHeart will facilitate harmonized country-level quality improvement and will generate the basis for international observational and registry-based randomized controlled trials, and post-marketing surveillance of devices and pharmacotherapies. Robust, internationally agreed, and standardized clinical outcome measures are therefore required.⁴

We aimed to produce a catalogue of hierarchically classified standardized heart failure outcome measures and their definitions in collaboration with the Heart Failure Association (HFA) and other international heart failure experts.

Methods

Data Science Group

The Data Science Group comprises of a project chair (CPG), medical experts (CW, AB, GB), project manager (CR), statistician (ABS), and data manager (SC).

Methodology

We followed the EuroHeart methodology for the development of data standards.¹² Briefly, this involved: (i) a systematic review of the literature to compose a list of 'candidate' outcome measures for heart failure; (ii) the selection and prioritization of variables by domain experts in the working group using a modified Delphi method; and (iii) the synthesis of outcome measure definitions based upon the existing literature, with critical review by the working group.

EuroHeart has already set out 'generic' cardiovascular outcomes measures that are applicable to all patients with cardiovascular disease, including heart failure.¹⁴ These include all-cause mortality, cardiovascular mortality, myocardial infarction, stroke, and new onset heart failure. This article should be considered in concert with these EuroHeart generic outcome measures.

Systematic review

We performed a systematic review of the literature on primary and secondary outcome measures reported in cardiovascular studies relevant to heart failure published between 1 January 2000 and 7 September 2023. This included peer reviewed randomized clinical trials and observational studies published in highly cited medical journals (Lancet, Journal of the American Medical Association, and New England Journal of Medicine). Definitions from existing heart failure registries, previous consensus documents, and contemporary guidelines were screened,^{1,5,7} with the synthesized results providing the basis for the modified Delphi process undertaken with the working group.

Working group

A working group was formed to identify clinically relevant outcome measures for the management of heart failure and agree upon their definitions for the variables via virtual meetings and polls. The working group included members of the EuroHeart Data Science Group, representatives from the HFA and ESC working groups (Appendix) as well as external heart failure experts. In total, the working group included 42 experts spanning 16 countries across Europe and North America.

Modified Delphi process

By means of a poll, each member of the working group independently reviewed the list of outcome measures derived from the literature review and voted to classify them as either a Level 1 (mandatory), Level 2 (optional), or to exclude the variable. This judgement was based upon the respondent's expertise concerning the importance, supporting evidence base, validity, reliability, feasibility, and applicability of each variable.

The threshold for inclusion as a Level 1 variable was at least 75% of participants voting for selection of the variable as Level 1.¹⁵ The threshold

for inclusion as a Level 2 variable was at least 75% of participants selecting for the variable either as Level 1 or Level 2. The results of the poll were presented and discussed among the working group during an online meeting held on 28 October 2023. Participants were invited to provide feedback during voting and there was a proposal made by the experts that additional variables to monitor disease progression and response to therapy over time would be valuable. This resulted in a re-vote on the complementary variables by means of an online poll. The agreed list of variables and their definitions were then reviewed by the working group for ratification.

Hierarchical grading

The working group classified outcome measures as Level 1 that should be collected for all participants, and Level 2 that may be selected by participating centres depending on their own requirements.

Implementation and application

The final set of Level 1 heart failure outcome measures will be programmed into the EuroHeart IT system by the EuroHeart Registry Technology Group. Data recorded on the IT platform will have an associated date of outcome occurrence and outcome multiplicity is allowed (except for the occurrence and date of death). The expected target population will be patients hospitalized after an index presentation of heart failure or after an outpatient visit for heart failure at a participating centre in EuroHeart countries. Data reporting and its statistical analysis will be in accordance with a statistical analysis plan.

Patient involvement

Patients were not invited to the vote on the candidate list of variables as per their request as they advised us that the process was too technical. The results of the poll have been presented to the ESC patient forum, which support this work.

Results

The systematic review retrieved 4728 studies, of which 861 (18%) met the inclusion criteria. Of these, 176 (20%) studies concerned heart failure. The potentially relevant outcome measures were extracted by members of the Data Science Group and were supplemented by those used in existing registries. In total, 34 candidate outcomes measures for heart failure were presented to the working group for independent voting. The final set of outcome measures was selected after a series of meetings and online polls between 16 July and 28 October 2023.

Hierarchical outcomes

Level 1 (mandatory) outcome measures

There were five outcome measures specific to heart failure that were deemed mandatory to collect and defined as Level 1 by the working group. These were in addition to the EuroHeart generic Level 1 cardiovascular outcome measures.

These were: (i) capture of left ventricular ejection fraction as a percentage. Where this is not possible, the category reported should be according to ESC guidance,¹⁶ (ii) all-cause hospitalization, (iii) heart failure hospitalization, (iv) implantation of left ventricular assist device, and (v) heart transplantation (Figure 1 and Table 1).

Level 2 (optional) outcome measures

There were two outcome measures that were deemed optional to collect and defined as Level 2 by the working group (Figure 1 and Table 1).

These were device implantation that included: transvenous pacemakers; leadless pacemakers; transvenous; subcutaneous implantable

cardioverter defibrillators; implantable cardioverter defibrillators; cardiac resynchronization therapy—pacemaker; and cardiac resynchronization therapy—defibrillator and resuscitated ventricular arrhythmia.

Complementary monitoring outcome measures

The working group proposed additional heart failure outcome measures that may be used for monitoring patients with heart failure, supplementary to the Level 1 and Level 2 heart failure outcome measures. These were: (i) concurrent presence of atrial fibrillation (AF), classified as first diagnosed AF, paroxysmal, persistent or permanent as defined by ESC guidelines¹⁷; (ii) N-terminal brain natriuretic peptide levels (NT-proBNP); (iii) estimated glomerular filtration rate (eGFR); (iv) change in left ventricular ejection fraction [i.e. the difference in the left ventricular ejection fraction (%) be measurement using the same imaging modality for calculating left ventricular ejection fraction]; and (v) New York Heart Association class (NYHA) (Figure 2 and Table 1).

Discussion

Through a structured and collaborative international expert-led process, we have identified and defined a catalogue of hierarchical outcome measures for patients with heart failure, including a complementary suite of monitoring variables. These will be used to measure the clinical outcomes for participants in EuroHeart and have wider utility for randomized clinical trials, prospective observational cohorts, and clinical registries outside EuroHeart.

The identification and optimal clinical management of heart failure is critical, given the increasing prevalence of heart failure and represents a significant health burden across Europe.³ Recent advances in guideline directed care have been associated with improved symptoms, better quality of life, reduced all-cause mortality, and fewer heart failure readmissions.^{18,19} Nonetheless, translating clinical guidelines into real world practice can be challenging. Indeed, previous work has shown that provision of guideline directed care for heart failure is variable between and within the European countries and this can be associated with adverse outcomes.^{20,21} One possible cause for this could be variability in defining key outcome measures⁴ which can impact heart failure hospitalization rates.²²

The EuroHeart heart failure outcome measures build upon existing cardiovascular outcomes relevant to patients with heart failure, including those by the ARC.^{5,7} There are similarities between these outcomes set: like ARC, all-cause, and cardiovascular-specific mortality were included as mandatory variables within EuroHeart. These are important safety outcomes that are necessary for regulatory approval of device and pharmacological interventions within cardiology.¹ Similarly, all-cause and heart failure hospitalizations were included, and are predictors of mortality and disease severity.²³ They are also important for patients,²³ and health services,²⁰ and in research are often components of a composite outcome.²⁴ Left ventricular assist device and heart transplantation likewise was included within both EuroHeart and ARC given their importance in advanced disease management and increasing within Europe.^{1,2}

Both organizations provide similar definitions for heart failure hospitalization, with emphasis on the admission to hospital being attributed primarily to heart failure and that the hospitalization must exceed 24 h or cross a calendar day. For worsening heart failure to be defined as an outcome measure, both organizations agree upon the requisite for clinical, biomarker and radiological markers, and augmentation of medical therapy from baseline.

Categorizing and defining heart failure outcomes in hierarchical fashion is a hallmark feature of EuroHeart data standards,^{8–11} which

Table 1 Level 1 and 2 heart failure outcome measures and definitions

Heart failure: Level 1 variables	
All-cause rehospitalization	Unscheduled hospitalization for any cause, defined as a being admitted for more than 24 h or past a calendar day. ^{a,b}
Heart failure rehospitalization	Hospital admission primarily related to heart failure (HF). Heart failure is a clinical syndrome characterized by typical symptoms (e.g. dyspnoea) and/or signs (e.g. ankle swelling), caused by a structural and/or functional cardiac abnormality (e.g. left ventricular hypertrophy or impairment), and associated with elevated natriuretic peptide levels and/or objective evidence of pulmonary or systemic congestion from a cardiogenic origin at rest or with exercise. Unplanned HF hospitalization is defined as a patient requiring an unscheduled hospital admission for a <i>primary diagnosis</i> of HF with a length of stay that either exceeds 24 h or crosses a calendar day (if hospital admission and discharge times are unavailable). To satisfy the criteria for a HF hospitalization, the patient must be admitted primarily for HF with signs, symptoms, and diagnostic testing results identical to those already described above. The patient must also require treatment for HF such as significant augmentation of oral diuretics, intravenous diuretics, or mechanical or surgical intervention for HF. ^{a–d}
Left ventricular ejection fraction	Left ventricular ejection fraction, ideally measured with echocardiography.
Heart transplantation	Receipt of surgery in which a failing, diseased heart is replaced with a healthier donor heart. ^e
Left ventricular assist device	Implant of a left ventricular assist device (LVAD).
Heart failure: level 2 variables	
Device implantation	Implantation of: <ul style="list-style-type: none"> • Transvenous permanent pacemaker is an electronic device that is implanted in the subcutaneous tissue and gives the heart an electrical stimulation through transvenous wires. • Leadless pacemaker is an electronic device that is implanted directly into the right ventricle. • Transvenous implantable cardioverter defibrillator (ICD) is a device that is used to correct abnormal heartbeat through transvenous wires. • Subcutaneous ICD is an ICD with a pre-sternal lead and is positioned between the latissimus dorsi and serratus muscle within the subcutaneous tissue. • Extravascular ICD is an ICD with a substernal lead and the device in the subcutaneous tissue of the lateral thorax. • Cardiac resynchronization therapy (CRT) device and pacemaker (CRT-P) is defined as a biventricular pacemaker that sends electrical stimulation to both ventricles. • CRT-D is a biventricular pacemaker and defibrillator.^{f,g}
Resuscitated ventricular tachyarrhythmia	The patient was successfully resuscitated and had return of spontaneous circulation from a ventricular tachyarrhythmia.
NYHA class	NYHA class I: no limitations of physical activity. Ordinary physical activity does not cause undue fatigue, palpitations, or dyspnoea. NYHA class II: slight limitation of physical activity. The patient is comfortable at rest. Ordinary physical activity results in fatigue, palpitations, or dyspnoea. NYHA class III: marked limitation of physical activity. The patient is comfortable at rest. Less than ordinary activity causes fatigue, palpitations, or dyspnoea. NYHA class IV: inability to carry on any physical activity without discomfort. Heart failure symptoms are present even at rest or with minimal exertion. ^{c,h}
Change in left ventricular ejection fraction	Left ventricular ejection fraction, ideally measured with echocardiography.
Atrial fibrillation	Patient has a concurrent diagnosis of any type of atrial fibrillation with heart failure. Atrial fibrillation is defined as a supraventricular tachyarrhythmia with uncoordinated atrial electrical activation and consequently ineffective atrial contraction. The minimum duration of an ECG tracing of atrial fibrillation required to establish the diagnosis of clinical atrial fibrillation is at least 30 s, or the entire 12-lead ECG. Atrial flutter is defined as a supraventricular tachyarrhythmia with coordinated but overly rapid atrial electrical activation, usually with some degree of atrioventricular (AV) node conduction block. The minimum duration of an ECG tracing of atrial flutter required to establish the diagnosis of clinical atrial flutter is at least 30 s, or the entire 12-lead ECG. ⁱ
NT-proBNP (ng/L)	Serum NT-proBNP in ng/L.
Estimated glomerular filtration rate (eGFR) (mL/min/1.73 m ²)	Estimated glomerular filtration rate (eGFR) in mL/min/1.73 m ² .

References

- ^aGénéreux P, Piazza N, Alu MC, et al. Valve Academic Research Consortium 3: updated endpoint definitions for aortic valve clinical research. *Eur Heart J* 2021;**42**:1825–1857. doi: 10.1093/eurheartj/ehaa799
- ^bHicks KA, Mahaffey KW, Mehran R, et al. 2017 Cardiovascular and stroke endpoint definitions for clinical trials. *Circulation* 2018;**137**:961–972. doi: 10.1161/circulationaha.117.033502
- ^cBozkurt B, Coats AJ, Tsutsui H, et al. Universal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure. *J Card Fail* 2021. doi: 10.1016/j.cardfail.2021.01.022
- ^dMcDonagh TA, Metra M, Adamo M, et al. 2023 Focused update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: developed by the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) with the special contribution of the Heart Failure Association (HFA) of the ESC. *Eur Heart J* 2023;**44**:3627–3639. doi: 10.1093/eurheartj/ehad195
- ^eMehra MR, Canter CE, Hannan MM, et al. The 2016 International Society for Heart Lung Transplantation listing criteria for heart transplantation: a 10-year update. *J Heart Lung Transplant* 2016;**35**:1–23. doi: 10.1016/j.healun.2015.10.023
- ^fGlikson M, Nielsen JC, Kronborg MB, et al. 2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy. *Eur Heart J* 2021;**42**:3427–3520. doi: 10.1093/eurheartj/ehab364
- ^gFriedman P, Murgatroyd F, Boersma LVA, et al. Efficacy and safety of an extravascular implantable cardioverter-defibrillator. *N Engl J Med* 2022;**387**:1292–1302. doi: 10.1056/NEJMoa2206485
- ^hMcDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. *Eur Heart J* 2021;**42**:3599–3726. doi: 10.1093/eurheartj/ehab368
- ⁱHindricks G, Potpara T, Dagres N, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. *Eur Heart J* 2021;**42**:373–498. doi: 10.1093/eurheartj/ehaa612




Figure 1 Distribution of votes for Level 1 and Level 2 heart failure outcome measures. Level 1 variable: Mandatory; Level 2 variable: Optional. A total of twenty-five international heart failure experts voted on the above outcome measures. Device implantation refers to leadless, single and dual chamber pacemakers, subcutaneous, extracardiac and subcutaneous defibrillators and cardiac resynchronisation therapies.

differs from previous work on heart failure outcomes set out by the ARC.⁵ Previous studies on heart failure have graded outcomes hierarchically based on their importance to both clinicians and regulators, which reflects an ambition from researchers and regulators to adopt a more pragmatic approach to analysis within research.^{25,26}

In contrast to ARC, recording left ventricular ejection fraction is a Level 1 outcome in EuroHeart. Current guidelines stratify heart failure according to left ventricular ejection fraction categories due to differences in the benefit of heart failure therapies and the association of worsening outcomes with declining left ventricular ejection fraction.^{16,21} However, heart failure with recovery or improvement in ejection fraction is increasingly recognized after implementing guideline-directed therapy and is associated with better long term outcomes.²⁷ Therefore, the working group agreed that left ventricular ejection fraction should be included both as a stand-alone variable and a variable that can be used for monitoring heart failure.

We also define complementary outcomes that may be used for the longitudinal evaluation of patients with heart failure, beyond traditional 'hard' outcomes.²⁸ These variables are either mechanistic or surrogate outcomes that, if collected prospectively could form the basis of further research. For example, the Valsartan Heart Failure Trial (Val-HeFT) investigated left ventricular ejection fraction as a surrogate outcome in patients with an ejection fraction below 35% that were randomized to valsartan or placebo. Compared to placebo, patients taking valsartan demonstrated an improvement in left ventric-

ular ejection fraction, improved survival at 12 months and decreased NT-proBNP level.²⁷ Given the advances in optimal medical therapy in heart failure, monitoring the left ventricular ejection fraction as well as other complementary variables could form the basis of observational research in real world settings. The working group emphasized the need for consistency in the method of measurement, for example serial echocardiogram scans.

The relationship between atrial fibrillation and heart failure is complex, because AF can be either the cause or consequence of heart failure.²⁹ Studies have shown that catheter ablation in patients with symptomatic paroxysmal or persistent AF in the context of severe left ventricular systolic dysfunction improves outcomes compared to medical therapy alone.^{30,31} This highlights the importance of recognizing and considering AF as a potentially therapeutic target in heart failure in contemporary registries or a surrogate marker for deterioration in heart failure.³² Other outcomes such as eGFR was included given renal impairment is well known to be greatly associated with mortality in patients with heart failure³³ and its prominence as a renal outcome in contemporary heart failure trials.^{34,35}

EuroHeart aims to reduce the burden of cardiovascular disease across Europe. The publication of these variables and their definitions will allow us to better understand the outcomes for people with heart failure. They will be integrated with the existing registries,⁸⁻¹¹ and incorporated into the EuroHeart IT platform. This will allow the patterns of clinical care and outcomes of patients to be evaluated

32. Dries D, Exner D, Gersh B, Domanski M, Waclawiw M, Stevenson L. Atrial fibrillation is associated with an increased risk for mortality and heart failure progression in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a retrospective analysis of the SOLVD trials. *J Am Coll Cardiol* 1998;**32**:695–703.
33. Damman K, Valente MAE, Voors AA, O'Connor CM, van Veldhuisen DJ, Hillege HL. Renal impairment, worsening renal function, and outcome in patients with heart failure: an updated meta-analysis. *Eur Heart J* 2013;**35**:455–469.
34. Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. *N Engl J Med* 2017;**377**:644–657.
35. Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. *N Engl J Med* 2019;**380**:347–357.
36. Aktaa S, Polovina M, Rosano G, Abdin A, Anguita M, Lainscak M et al. European Society of Cardiology quality indicators for the care and outcomes of adults with heart failure. Developed by the Working Group for Heart Failure Quality Indicators in collaboration with the Heart Failure Association of the European Society of Cardiology. *Eur J Heart Fail* 2022;**24**:132–142.
37. Bowman L, Baras A, Bombien R, Califf RM, Chen Z, Gale CP et al. Understanding the use of observational and randomized data in cardiovascular medicine. *Eur Heart J* 2020;**41**:2571–2578.
38. Wilkinson C, Bhatta A, Smith AB, Dwight J, Sanders J, Gale CP. Embracing the promise of patient reported outcome measures in cardiology. *Eur Heart J Qual Care Clin Outcomes* 2024.
39. Kornowski R. Patient-reported outcome measures in cardiovascular disease. *Eur Heart J Q Care Clin Outcomes* 2021;**9**:119–127.